A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
Anemia is a complication of chronic kidney disease (CKD), primarily due to insufficient secretion of erythropoietin (EPO) by the kidney. Erythropoiesis-stimulating agents (ESAs) are used to treat anemia associated with chronic kidney disease. A poor response to ESAs has been associated with inflamma...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2020.00393/full |
| _version_ | 1818495580193685504 |
|---|---|
| author | Zhipeng Yan Gaosi Xu |
| author_facet | Zhipeng Yan Gaosi Xu |
| author_sort | Zhipeng Yan |
| collection | DOAJ |
| description | Anemia is a complication of chronic kidney disease (CKD), primarily due to insufficient secretion of erythropoietin (EPO) by the kidney. Erythropoiesis-stimulating agents (ESAs) are used to treat anemia associated with chronic kidney disease. A poor response to ESAs has been associated with inflammation. Inflammation can affect erythrocytes and its production in many ways, but mainly through the inflammatory cytokine IL-6 to stimulate the synthesis of hepcidin in the liver. Hepcidin causes iron insufficiency, which causes erythrocytes to fail to mature normally. In addition, inhibition of bone marrow erythroid precursor cells by inflammatory cytokines such as IL-1 and TNF-α also affects bone marrow hematopoiesis. These cytokines are also important factors leading to EPO resistance. Roxadustat is a new drug for the treatment of renal anemia. In addition to promoting the production of EPO, clinical trials have shown that it can significantly reduce hepcidin and can potentially be used for the treatment of inflammation-induced anemia in CKD. |
| first_indexed | 2024-12-10T18:22:23Z |
| format | Article |
| id | doaj.art-5afe0a613bd34a3880c78060efbe9c79 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-10T18:22:23Z |
| publishDate | 2020-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-5afe0a613bd34a3880c78060efbe9c792022-12-22T01:38:10ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2020-08-01710.3389/fmed.2020.00393519597A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor RoxadustatZhipeng YanGaosi XuAnemia is a complication of chronic kidney disease (CKD), primarily due to insufficient secretion of erythropoietin (EPO) by the kidney. Erythropoiesis-stimulating agents (ESAs) are used to treat anemia associated with chronic kidney disease. A poor response to ESAs has been associated with inflammation. Inflammation can affect erythrocytes and its production in many ways, but mainly through the inflammatory cytokine IL-6 to stimulate the synthesis of hepcidin in the liver. Hepcidin causes iron insufficiency, which causes erythrocytes to fail to mature normally. In addition, inhibition of bone marrow erythroid precursor cells by inflammatory cytokines such as IL-1 and TNF-α also affects bone marrow hematopoiesis. These cytokines are also important factors leading to EPO resistance. Roxadustat is a new drug for the treatment of renal anemia. In addition to promoting the production of EPO, clinical trials have shown that it can significantly reduce hepcidin and can potentially be used for the treatment of inflammation-induced anemia in CKD.https://www.frontiersin.org/article/10.3389/fmed.2020.00393/fullchronic kidney diseaseroxadustatinflammationhypoxia inducible factorerythropoietin |
| spellingShingle | Zhipeng Yan Gaosi Xu A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat Frontiers in Medicine chronic kidney disease roxadustat inflammation hypoxia inducible factor erythropoietin |
| title | A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat |
| title_full | A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat |
| title_fullStr | A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat |
| title_full_unstemmed | A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat |
| title_short | A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat |
| title_sort | novel choice to correct inflammation induced anemia in ckd oral hypoxia inducible factor prolyl hydroxylase inhibitor roxadustat |
| topic | chronic kidney disease roxadustat inflammation hypoxia inducible factor erythropoietin |
| url | https://www.frontiersin.org/article/10.3389/fmed.2020.00393/full |
| work_keys_str_mv | AT zhipengyan anovelchoicetocorrectinflammationinducedanemiainckdoralhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustat AT gaosixu anovelchoicetocorrectinflammationinducedanemiainckdoralhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustat AT zhipengyan novelchoicetocorrectinflammationinducedanemiainckdoralhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustat AT gaosixu novelchoicetocorrectinflammationinducedanemiainckdoralhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustat |